Upcoming Results and Conference Call Schedules, New Office Facility, and Stock Price Movements-Analyst Notes on Biogen, Actavis, Bristol-Myers, AbbVie, and Baxter

NEW YORK, April 9, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Actavis Plc (NYSE: ACT), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV), and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Biogen Idec Inc. Analyst Notes 

On March 31, 2014, Biogen Idec Inc. (Biogen) announced that the Company plans to release its Q1 2014 results on April 23, 2014, before the opening of the financial markets. Following the earnings release, the Company will host a live webcast at 8:00 a.m. ET to discuss the results. According to Zacks Investment research data, the consensus EPS forecast for Q1 2014 is $2.56.For Q4 2013, the Company reported total revenues of $2.0 billion, up 38.6% YoY, while the net income came in at $457.3 million, up 56.5% YoY. The full analyst notes on Biogen Idec Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04092014/BIIB/report.pdf

Actavis Plc Analyst Notes 

On April 2, 2014, Actavis Plc (Actavis) announced the opening of its new regional office in Singapore that will serve as the Company's headquarters for the Asia Pacific and Africa (APACA) region. In addition, the Company informed that its operating subsidiary Drug Houses of Australia Pte Ltd (DHA) in Singapore will be merged into the Actavis Brand. Paul Bisaro, Chairman and CEO of Actavis, commented, "The opening of our new regional headquarters in Singapore is an important step in Actavis' global expansion and further evidence of our commitment to being a leading provider of a full range of pharmaceutical products in the region." The full analyst notes on Actavis Plc are available to download free of charge at:

http://www.AnalystsReview.com/04092014/ACT/report.pdf

Bristol-MyersSquibb Co. Analyst Notes 

On April 1, 2014, bio pharmaceuticals firm - Bristol-Myers Squibb Co. (Bristol-Myers) announced that it plans to release its Q1 2014 results on April 29, 2014. The earnings release will be followed by a conference call at 9:00 a.m. EDT in which the Company's executives will review the results and answer analysts and investors' queries. According to Zacks Investment research data, the consensus EPS forecast for Q1 2014 is $0.46.For Q4 2013, the Company reported net earnings of $842 million, or $0.51 per share on a non-GAAP basis, beating analysts'estimates $0.43 polled by Thomson Reuters.

The Company had predicted 2014 GAAP EPS in the range of $1.75 - $1.90 and non-GAAP EPS between$1.65 - $1.80. The full analyst notes on Bristol-Myers Squibb Co. are available to download free of charge at:

http://www.AnalystsReview.com/04092014/BMY/report.pdf

AbbVie Inc. Analyst Notes 

On April 4, 2014, AbbVie Inc.'s (AbbVie) stock declined 2.43% to end the trading session at $52.20, following the S&P 500 which lost 1.25% over the same day. AbbVie's stock opened the session at $53.78 and oscillated in the range of $52.05 - $54.44. A total of 7.01 million shares were traded, which was above its 30-day average volume of 5.84 million. Over the past twelve months, the stock has returned 26.36% outperforming the S&P 500 which returned 20.07% over the same period. The full analyst notes on AbbVie Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04092014/ABBV/report.pdf

Baxter International Inc. Analyst Notes 

On April 3, 2014, Baxter International Inc. (Baxter) announced that the Company plans to hold its quarterly conference call to discuss its Q1 2014 results on April 17, 2014 at 7:30 a.m. CT.  According to Zacks Investment research data, the consensus EPS forecast for Q1 2014 is $1.11.The Company in its Q4 2013 and full year 2013 earnings release had predicted a sales growth of nearly 13 to 14%, excluding the impact of foreign currency for Q1 2014.In addition, the Company said that it is hopeful of achieving earnings, before special items, of $1.06 to $1.09 per diluted share (or GAAP earnings of $1.00 to $1.03 per diluted share including approximately $0.06 per diluted share of intangible asset amortization expense) for Q1 2014. The full analyst notes on Baxter International Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04092014/BAX/report.pdf

About Analysts Review

We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsReview.com

SOURCE Analysts Review